Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

321 questions · 328 findings · 23 reviews · Skin

No studies found 119 · 36.3%GRADE not reported 15 · 4.6%Very low 64 · 19.5%Low 72 · 22%Moderate 41 · 12.5%High 17 · 5.2%

Wax therapy vs foot soaks

Tertiary outcome: prevention and treatment of other skin changes (number of feet being fissure‐ and callous‐free at 6 weeks) · skin changes caused by nerve damage in leprosy

It is very uncertain whether wax therapy changes tertiary outcome: prevention and treatment of other skin changes… compared with foot soaks (very low certainty).

1 finding from 1 review

NB‐UVB vs medium‐dose UVA‐1 phototherapy (50 J/cm²)

Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

Narrowband UVB phototherapy may leads to lower primary outcome: Adverse effects compared with medium‐dose UVA‐1 phototherapy (50 J/cm²) (low certainty).

1 finding from 1 review

NB‐UVB vs medium‐dose UVA‐1 phototherapy (50 J/cm²)

Secondary outcome: Improvement of disease damage ‐ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

The review found no eligible studies for this question.

1 finding from 1 review

NB‐UVB vs low‐dose UVA‐1 phototherapy (20 J/cm²)

Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review

NB‐UVB vs low‐dose UVA‐1 phototherapy (20 J/cm²)

Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

Narrowband UVB phototherapy may leads to lower primary outcome: Adverse effects compared with low‐dose UVA‐1 phototherapy (20 J/cm²) (low certainty).

1 finding from 1 review

NB‐UVB vs low‐dose UVA‐1 phototherapy (20 J/cm²)

Secondary outcome: Improvement of disease activity (skin softening) · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review

NB‐UVB vs low‐dose UVA‐1 phototherapy (20 J/cm²)

Secondary outcome: Improvement of disease damage ‐ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

The review found no eligible studies for this question.

1 finding from 1 review

NB‐UVB vs medium‐dose UVA‐1 phototherapy (50 J/cm²)

Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review